Alnuctamab

Alnuctamab (EM901) is a bispecific T-cell engager targeting BCMA and CD3, belonging to an asymmetric two-armed humanized IgG1 antibody. Alnuctamab can simultaneously bind to BCMA expressed on the surface of myeloma cells and CD3 molecules on the surface of T cells, recruiting T cells to kill tumors. Alnuctamab is used for the research of multiple myeloma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) [1][2][3].

Product Specifications

CAS Number

[2296827-07-9]

Product Name Alternative

EM901; CC-93269

UNSPSC

12352203

Target

CD3

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/alnuctamab.html

Purity

99.89

Solubility

10 mM in DMSO

Smiles

[Alnuctamab]

Molecular Weight

(192.13 kDa)

References & Citations

[1]Danny V Jeyaraju, et al. Suppression of Myeloid Cell-Derived Proinflammatory Cytokines with Celmod Agents: Implications for CRS with T-Cell Engagers (TCEs) . Blood (2022) 140 (Supplement 1) : 7070–7071.|[2]Wong S W, et al. Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-cell maturation antigen (BCMA) x CD3 T-cell engager (TCE), in patients (pts) with relapsed/refractory multiple myeloma (RRMM) : results from a phase 1 first-in-human clinical study[J]. Blood, 2022, 140 (Supplement 1) : 400-402.|[3]Paiva B, et al. Synergistic antitumor activity of alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA 2+ 1 T cell engager (TCE), and celmod agents in multiple myeloma (MM) preclinical models. Blood, 2022, 140 (Supplement 1) : 7054-7055.